GeoVax Labs Inc.

AI Score

XX

Unlock

1.18
0.10 (9.26%)
At close: Apr 02, 2025, 3:59 PM
1.15
-2.19%
After-hours: Apr 02, 2025, 06:59 PM EDT
9.26%
Bid 1.09
Market Cap 16.33M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -4.82
PE Ratio (ttm) -0.24
Forward PE -2.26
Analyst Buy
Ask 1.2
Volume 379,688
Avg. Volume (20D) 620,171
Open 1.10
Previous Close 1.08
Day's Range 1.09 - 1.21
52-Week Range 1.03 - 11.18
Beta 3.07

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, ch...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 17
Stock Exchange NASDAQ
Ticker Symbol GOVX
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for GOVX stock is "Buy." The 12-month stock price forecast is $16.5, which is an increase of 1298.31% from the latest price.

Stock Forecasts

Earnings Surprise

GeoVax Labs has released their quartely earnings on Mar 27, 2025:
  • Revenue of $864.58K misses estimates by $2.11M, with Infinity% YoY growth.
  • EPS of -0.3 exceeds estimates by 0.49, with 92.39% YoY growth.
  • 4 months ago
    -16.92%
    GeoVax Labs shares are trading lower. The company ... Unlock content with Pro Subscription
    4 months ago
    +3.5%
    GeoVax Labs shares are trading lower. The company reported Q3 financial results.